Hikal Q3 FY26: Revenue, EBITDA surge amid regulatory recovery
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
The new OMR facility, located in Chennai’s medical hub, is close to leading hospitals and offers excellent road and air connectivity
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
The company’s EBITDA margin remained resilient above 20%
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Subscribe To Our Newsletter & Stay Updated